$ 44.11

$ 0.14 | 0.32%


As of January 16, 2020 Close

Press Release

Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020

Company Release - 1/7/2020 8:30 AM ET

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present a corporate overview and updated clinical development plans for its lead candidates ZW25 and ZW49 at the upcoming 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 3:30 p.m. PT.

The presentation will be webcast live and available for replay on Zymeworks’ website at

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit

Investor Inquiries:
Ryan Dercho, Ph.D.
(604) 678-1388

Tiffany Tolmie
(604) 678-1388

Media Inquiries:
Kavita Shah, Ph.D.
(604) 678-1388

Source: Zymeworks Inc.

Copyright 2020, © S&P Global Market Intelligence  Terms of Use